IBD:放射疗法治疗IBD合并前列腺癌的不良反应发生率

2020-04-12 MedSci原创 MedSci原创

炎症性肠病(IBD)患者可能因前列腺癌的放射治疗而出现相关并发症。然而,可用数据有限,因此,本项研究旨在对患有前列腺癌的IBD患者的放射治疗进行相关研究。

背景:炎症性肠病(IBD)患者可能因前列腺癌的放射治疗而出现相关并发症。然而,可用数据有限,因此,本项研究旨在对患有前列腺癌的IBD患者的放射治疗进行相关研究。

方法:本项研究为一项回顾性队列研究。纳入了1996-2015年间诊断并治疗过前列腺癌的IBD患者。评估了在癌症诊断的6、12和24个月内IBD,IBD相关的住院治疗和IBD相关的手术事件,以及1、2和5年的存活率。IBD的复发是由治疗医师记录的,因此治疗也相应改变。

结果:本项研究共确定了一百名患有IBD和前列腺癌的患者。47例接受了外部束放射治疗或近距离放射治疗,53例接受了非放射治疗。在癌症诊断后的6个月(10.6%VS 5.7%)和6-12个月(4.3% VS 1.9%)内,接受放射治疗的患者的炎症性肠疾病发作高2倍。在多元逻辑回归分析中,放射治疗(OR:4.82; 95%置信区间为1.15–20.26)是复发的重要预测指标。但是,与IBD相关的住院或手术的比率没有显着差异。

结论:在这项回顾性,多中心研究中,接受放射治疗的患者在前列腺癌确诊后的第一年内发现的疾病复发发生率增加了2倍,但与IBD相关的住院或手术没有差异。

原始出处L:

inda A Feagins, et al. Rates of Adverse IBD-Related Outcomes for Patients With IBD and Concomitant Prostate Cancer Treated With Radiation Therapy. Inflammatory Bowel Diseases.2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1840613, encodeId=4f35184061375, content=<a href='/topic/show?id=9401204912f' target=_blank style='color:#2F92EE;'>#不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20491, encryptionId=9401204912f, topicName=不良反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Sep 02 05:20:42 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826597, encodeId=37a1182659e05, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Jan 15 23:20:42 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928588, encodeId=9ded192858863, content=<a href='/topic/show?id=54495e39233' target=_blank style='color:#2F92EE;'>#放射疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57392, encryptionId=54495e39233, topicName=放射疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Sat Jul 18 15:20:42 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263561, encodeId=b097126356177, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Apr 14 12:20:42 CST 2020, time=2020-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040712, encodeId=5cd11040e12f0, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Apr 13 00:20:42 CST 2020, time=2020-04-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1840613, encodeId=4f35184061375, content=<a href='/topic/show?id=9401204912f' target=_blank style='color:#2F92EE;'>#不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20491, encryptionId=9401204912f, topicName=不良反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Sep 02 05:20:42 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826597, encodeId=37a1182659e05, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Jan 15 23:20:42 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928588, encodeId=9ded192858863, content=<a href='/topic/show?id=54495e39233' target=_blank style='color:#2F92EE;'>#放射疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57392, encryptionId=54495e39233, topicName=放射疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Sat Jul 18 15:20:42 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263561, encodeId=b097126356177, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Apr 14 12:20:42 CST 2020, time=2020-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040712, encodeId=5cd11040e12f0, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Apr 13 00:20:42 CST 2020, time=2020-04-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1840613, encodeId=4f35184061375, content=<a href='/topic/show?id=9401204912f' target=_blank style='color:#2F92EE;'>#不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20491, encryptionId=9401204912f, topicName=不良反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Sep 02 05:20:42 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826597, encodeId=37a1182659e05, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Jan 15 23:20:42 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928588, encodeId=9ded192858863, content=<a href='/topic/show?id=54495e39233' target=_blank style='color:#2F92EE;'>#放射疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57392, encryptionId=54495e39233, topicName=放射疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Sat Jul 18 15:20:42 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263561, encodeId=b097126356177, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Apr 14 12:20:42 CST 2020, time=2020-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040712, encodeId=5cd11040e12f0, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Apr 13 00:20:42 CST 2020, time=2020-04-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1840613, encodeId=4f35184061375, content=<a href='/topic/show?id=9401204912f' target=_blank style='color:#2F92EE;'>#不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20491, encryptionId=9401204912f, topicName=不良反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Sep 02 05:20:42 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826597, encodeId=37a1182659e05, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Jan 15 23:20:42 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928588, encodeId=9ded192858863, content=<a href='/topic/show?id=54495e39233' target=_blank style='color:#2F92EE;'>#放射疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57392, encryptionId=54495e39233, topicName=放射疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Sat Jul 18 15:20:42 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263561, encodeId=b097126356177, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Apr 14 12:20:42 CST 2020, time=2020-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040712, encodeId=5cd11040e12f0, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Apr 13 00:20:42 CST 2020, time=2020-04-13, status=1, ipAttribution=)]
    2020-04-14 bnurmamat
  5. [GetPortalCommentsPageByObjectIdResponse(id=1840613, encodeId=4f35184061375, content=<a href='/topic/show?id=9401204912f' target=_blank style='color:#2F92EE;'>#不良反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20491, encryptionId=9401204912f, topicName=不良反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Sep 02 05:20:42 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826597, encodeId=37a1182659e05, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Jan 15 23:20:42 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928588, encodeId=9ded192858863, content=<a href='/topic/show?id=54495e39233' target=_blank style='color:#2F92EE;'>#放射疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57392, encryptionId=54495e39233, topicName=放射疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Sat Jul 18 15:20:42 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263561, encodeId=b097126356177, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Apr 14 12:20:42 CST 2020, time=2020-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040712, encodeId=5cd11040e12f0, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Apr 13 00:20:42 CST 2020, time=2020-04-13, status=1, ipAttribution=)]
    2020-04-13 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

GUT:肾素-血管紧张素系统的失衡可能导致IBD的肠道炎症和纤维化

背景及目的:本项研究旨在评估肾素-血管紧张素系统(RAS)对肠道炎症和纤维化的影响。

Gastroenterology: 依他西莫在溃疡性结肠炎患者的疗效和安全性分析

Etrasimod(APD334)是一种口服选择性鞘氨醇1-磷酸受体调节剂,准备开发用于免疫介导的炎症性疾病的治疗。本项研究评估了依拉西莫在中度至重度活动性溃疡性结肠炎(UC)患者中的疗效和安全性。

Gastroenterology:炎症性肠病患者肠道菌群变化研究

研究证实炎症性肠病患者肠道部分细菌丰度存在差异

Gastroenterology:Vedolizumab皮下注射在溃疡性结肠炎患者中的疗效和安全性

与维多珠单抗维持治疗的静脉内给药相比,一些患者可能更喜欢维多珠单抗的皮下制剂进行维持治疗。本项研究对中度至重度活动性溃疡性结肠炎患者进行了皮下维多珠单抗的维持治疗进行了相关研究。